Telehealth disparities are driven by more than language barriers, according to experts outlining systemic factors and ...

Objective Disease activity both between and within patients with SLE is highly variable, yet factors driving this variability remain unclear. This study aimed to identify predictors of variability in ...

The agreement hands Biogen as much as $250 million in exchange for milestone payments and sales royalties for litifilimab, ...

The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the ...

Biogen has bagged $250 million to advance a key pipeline prospect. | Biogen has bagged $250 million to advance a key pipeline ...

We are excited to collaborate with Biogen on litifilimab,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “Royalty Pharma offers tailored, win-win funding solutions for ...

Background SLE is a systemic autoimmune disease with a large number of common risk gene variants, but several rare gene ...

Patients with CLE who have specific patient characteristics may have lower treatment response than patients who do not have these characteristics.

The FDA has granted Fast Track designation to ADI-001 for the treatment of refractory systemic lupus erythematosus with extrarenal involvement.

A NEW Swedish study has found that menopausal hormone therapy (MHT) may be associated with an increased risk of developing ...

The following is a summary of “Barriers and facilitators to sustaining a lupus patient decision aid in regular rheumatology ...

Alumis Inc. will merge with a Southern California drug developer in a deal that extends the combined companies' cash into ...